Connect with us

Technology

Genomics Market to Reach $70.52 Billion by 2031, Driven by Increasing Incorporation of Genomic Data in Clinical Workflows and Increasing Funding and Investments in Genomics Projects – Exclusive Report by Meticulous Research®

Published

on

REDDING, Calif., Sept. 24, 2024 /PRNewswire/ — According to a new market research report titled, ‘Genomics Market Size, Share, Forecast, & Trends Analysis by Technology (Sequencing, Microarray, Nucleic Acid Extraction), Application (Drug Discovery, Diagnostic, Research), Offering (Instrument, Consumables, Software), End User—Global Forecast to 2031.

The genomics market is projected to reach $70.52 billion by 2031, at a CAGR of 11.1% from 2024 to 2031.

Download FREE PDF Brochure Of Genomics Market –
https://www.meticulousresearch.com/download-sample-report/cp_id=1262

The rising prevalence of genetic diseases, the increasing incorporation of genomic data in clinical workflows, increasing funding and investments in genomics projects, growing applications of genomics in the healthcare sector, rising pharmaceutical R&D expenditures, and increasing healthcare spending are key factors driving the growth of the genomics market. However, concerns over the security & privacy of genomic data and the lack of standardized approaches in genomics are factors restraining the growth of this market.

Furthermore, the rising adoption of personalized medicines and gene therapies is expected to create opportunities for the players operating in the genomics market. However, the shortage of skilled bioinformatics & genomics personnel and the commercialization & scaling of genomic technologies are major challenges impacting market growth. READ MORE

Increasing Funding and Investments in Genomics Projects Reshaping the Market Landscape

Pharmaceutical and biotechnology companies have been increasingly focused on genomic research since 2003 – the year of completion and publishing of the full sequence of the entire human genome. Furthermore, increasing funding for genomic research, the development of advanced sequencing technologies & bioinformatics tools, and the reducing costs of genomic studies are generating opportunities for pharmaceutical and biotechnology companies to engage more in the research and development of personalized/precision medicine, targeted therapeutics, and vaccines. These factors have also helped companies as well as academic & research institutes to conduct more studies focused on mapping and identifying variants and studying the mechanisms of various rare and genetic diseases.

Get Insightful Data On Regions, Market Segments, Customer Landscape, And Top Companies (Charts, Tables, Figures And More) – https://www.meticulousresearch.com/request-sample-report/cp_id=1262

The pharmaceutical industry is also investing in genomic data-sharing initiatives to accelerate the research and development of novel personalized therapies. Also, research and academic institutes are partaking in genomic studies and collaborating with key pharmaceutical companies to exchange genomic data and discover new personalized therapies for various rare and genetic diseases. Some of the recent funding and investments supporting genomics studies are as follows:

In December 2022, the U.K. government announced $217 million (€175 million) in funding for genomics research, including $130 million (€105 million) to boost the diagnosis of rare genetic diseases in newborns.In September 2022, the Centers for Disease Control and Prevention (CDC) announced $90 million in funding over the next five years to support the Pathogen Genomics Centers of Excellence (PGCoE) network, which is aimed at accelerating innovations and improving technical capacities in molecular epidemiology, pathogen genomes, and bioinformatics for the prevention and control of microbial threats to public health.In March 2022, the National Institutes of Health (NIH) allocated $89 million in funding for advancing genome editing projects to develop new technologies and novel research approaches in the somatic cell genome editing program.According to the UK Parliament article published in December 2022, the U.K. government provided $27 million (£22 million) in funding to Genomics England for sequencing 15,000 to 25,000 participants from diverse backgrounds by 2025 and tackling health inequalities in genomic medicine.

Automation in Next-Generation Sequencing (NGS): A Key Trend in the Genomics Market

The ability to sequence the genes of any organism for clinical and research purposes has proved to be a game changer for public health. Portable handheld sequencing devices are paving the way for the growth of the genomics market, making sequencing cheaper, simpler, and faster without the need for large clinical laboratories. Real-time sequencing has enabled researchers and physicians to quickly access sequencing data and act instantly. Portable nanopore-based sequencers can sequence the entire genome in less than $1,000. Additionally, automating NGS library preparation has helped researchers improve their library quality and achieve consistent yields, enabling the generation of reliable and reproducible NGS data.

NGS automation has also enhanced the efficiency of sequencing in terms of time and cost. The risk of contamination is greatly decreased by reducing human interactions with reagents and samples. According to a study that analyzed the cost breakdown for genome sequencing, lab personnel account for around 15% of the total cost of sequencing in a conventional clinical laboratory. A similar study showed that when an automated system is used for sample preparation, the cost of laboratory personnel decreases to around 4% of the total cost. Thus, automation optimizes & streamlines NGS workflows.

Explore the Key Market Segments Driving Growth (Download Free Sample) – https://www.meticulousresearch.com/download-sample-report/cp_id=1262

Genomics Market Analysis: Key Segmental Findings

By offering: In 2024, the consumables segment is expected to account for the largest share of 68.9% of the genomics market. The segment’s large market share can be attributed to the increasing demand for consumables due to the growing number of genomic tests, more recurring purchases of consumables compared to instruments, and the increasing prevalence of genetic diseases. For instance, according to a report published by MJH Life Sciences (U.S.) in 2022, approximately 300,000 babies are born with sickle cell disease per year globally, and nearly 5% of the world’s population is affected by the disease.By Technology: In 2024, the sequencing segment is expected to register the highest CAGR of 15.3% during the forecast period 2024–2031. The high growth of this segment is driven by the growing adoption of NGS for sequencing, the rising prevalence of cancer & the expanding application of NGS in cancer treatment & research, the declining costs of NGS, and technological advancements in NGS. Additionally, the growing demand for NGS automation, and the development of portable sequencing technologies also support the growth of this segment.

Geographic Analysis:

North America Poised to Dominate the Genomics Market in 2024

Based on geography, the genomics market is segmented into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. In terms of value, in 2024, North America is expected to account for the largest share of 53.3% of the genomics market. This market is projected to reach $36.2 billion by 2031. North America’s dominant position in the genomics market is attributed to government initiatives toward the development of genomic medicine, the increased use of genomics since the COVID-19 pandemic, increasing research in the field of genomics, and the advanced healthcare infrastructure in the region.

Have specific research needs? Request a customized research report – https://www.meticulousresearch.com/request-customization/cp_id=1262

In addition, North America is home to numerous renowned research institutions, universities, and organizations dedicated to genomics research—examples include the Broad Institute, Harvard University, MIT, and the National Institutes of Health (NIH) in the U.S., as well as the University of Toronto, McGill University, and the Ontario Institute for Cancer Research (OICR) in Canada. In North America, genomics is a multidisciplinary field encompassing research, technology development, and applications related to the study of genomes (complete sets of genes within an organism’s DNA). In North America, genomics has been a significant and rapidly evolving field with broad applications in various areas of science and medicine.

In 2024, the U.S. is expected to account for the dominant share of 91.6% of the genomics market in North America. The country’s large market share is mainly attributed to the availability of advanced technologies & resources for healthcare, research funding, government initiatives to promote precision medicine, high public & private investments in genomics, and the availability of skilled professionals in the country.

Asia-Pacific: The Fastest-growing Regional Market

The genomics market in Asia-Pacific is projected to register the highest CAGR of 13.8% during the forecast period. In 2024, China is expected to account for the largest share of 38.9% of the genomics market in Asia-Pacific. Economic growth in many Asia-Pacific countries has increased government focus on the healthcare sector in terms of investments aimed at improving access to healthcare facilities and building better healthcare infrastructure. Rapid urbanization, the need to manage the growing burden of infectious diseases, efforts to improve access to diagnostic services, and rising awareness regarding health and treatment availability are driving the growth of this market. Moreover, rising middle-class populations and their disposable incomes, increasing health insurance penetration, the growing potential of personalized therapies, and public and private investments are expected to support market growth during the forecast period.

Funding from public & private organizations for the development of innovative genomic medicine has increased China’s focus on strengthening its genomics market.

Some of the recent key developments in this market are as follows:

In January 2023, Qitan Technology Co. Ltd. (China) raised $104 million (¥700 million) in a series C round to improve its nanopore sequencing devices and expand its market in China.In June 2022, Chinese sequencing technology company Axbio secured $100 million in Series B funding. The funds supported the development and commercialization of its nanopore-based sequencer and the building of a manufacturing facility.In 2016, the People’s Republic of China announced $9 billion in funding for a 15-year project to collect, analyze, and sequence genomic data and become a global leader in precision medicine.

Need Insights on Regional Data? Check Out Our Detailed Analysis (Download Free Sample) –

Genomics Market: Competition Analysis

This report offers a competitive analysis based on an extensive assessment of the leading players’ product portfolios, geographic presence, and key growth strategies adopted over the past 3–4 years. Major companies in the genomics market have implemented various strategies to expand their product offerings and global footprints and augment their market shares. The key strategies followed by most companies in the genomics market include product launches, expansions, agreements, collaborations, and partnerships. The key players operating in the genomics market include Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Eppendorf SE (Germany), Myriad Genetics, Inc. (U.S.), Revvity, Inc. (Formerly PerkinElmer, Inc.) (U.S.), and BGI Genomics Co. Ltd (China).

The report includes a competitive dashboard that summarizes the market positions of the 20 profiled market players in four quadrants, namely Industry Leaders, Differentiators, Emerging Companies, and Vanguards. These companies are positioned based on various parameters, including revenue, depth of offerings, brand equity, geographic presence, innovation, and organic & inorganic growth strategies. Illumina, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), QIAGEN N.V (U.S.), and Danaher Corporation (U.S.) were positioned in the Industry Leaders quadrant.

Learn About the Top Companies Influencing Market Dynamics (Download Free Sample) –

Genomics Industry Overview: Latest Strategic Developments from Key Industry Players

In January 2024, Thermo Fisher Scientific Inc. (U.S.) received GMP approval from the Italian Medicines Agency (AIFA) for its manufacturing facility for RNA-based products in Monza, Italy.In January 2024, Thermo Fisher launched the Axiom PangenomiX Array, a comprehensive and ethnically diverse genomic coverage on a high-throughput microarray that delivers multi-disease and pharmacogenomic research analysis across global populations.In January 2024, Illumina, Inc. (U.S.) extended its collaboration with Janssen Research & Development, LLC (U.S.) for the development of Illumina’s novel Molecular Residual Disease (MRD) assay, a Whole-genome Sequencing (WGS) multi-cancer research solution that detects circulating tumor DNA (ctDNA).In January 2024, QIAGEN N.V. (Netherlands) announced plans to open its regional headquarters in Riyadh, Saudi Arabia, to further strengthen its footprint in the region. QIAGEN had also signed a Memorandum of Understanding (MoU) with Saudi Arabia’s Ministry of Health, addressing various public health and infection control initiatives.In December 2023, Danaher Corporation (U.S.) acquired Abcam plc (U.K.). Abcam operates as a standalone company and brand within Danaher’s Life Sciences segment, furthering Danaher’s strategy to help map complex diseases and accelerate drug discovery.In September 2023, Integrated DNA Technologies, a subsidiary of Danaher Corporation (U.S.), launched xGen NGS products designed exclusively for the Ultima Genomics UG 100TM platform.In June 2023, Agilent Technologies, Inc. (U.S.) launched Agilent 6495D LC/TQ and Agilent Revident LC/Q-TOF. The company also launched Agilent MassHunter Explorer Profiling software and the new Agilent ChemVista library manager software.In May 2022, Bio-Rad Laboratories, Inc. (U.S.) launched the CFX Duet Real-Time PCR System to support researchers in developing singleplex and duplex quantitative PCR (qPCR) assays.In December 2021, Pacific Biosciences of California, Inc. (U.S.) launched its HiFiViral SARS-CoV-2 Kit, which helps detect the Omicron Variant and provides information important for public health.

IMMEDIATE DELIVERY AVAILABLE | BUY THIS RESEARCH REPORT (Insights, Charts, Tables, Figures and More) – https://www.meticulousresearch.com/Checkout/61289368

Scope of the Report:

Genomics Market Assessment—by Offering

ConsumablesInstrumentsSoftwareServices

Genomics Market Assessment—by Technology

Polymerase Chain Reaction (PCR)SequencingNext-generation Sequencing (NGS)Other Sequencing TechnologiesNucleic Acid Extraction & PurificationMicroarrayOther Technologies

Note: Other sequencing technologies include pyrosequencing, degradome sequencing, Sanger sequencing, Chromatin Immunoprecipitation (ChIP) sequencing, and methylation sequencing.

Note: (Other technologies include cell counting, transfection, and gene editing.)

Click Here For More Details – https://www.meticulousresearch.com/download-sample-report/cp_id=1262

Genomics Market Assessment—by Application

DiagnosticsDrug Discovery & DevelopmentLife Sciences ResearchCancer ResearchStem Cell ResearchOther Life Sciences ResearchOther Applications

Note: Other life sciences research applications include cardiovascular diseases, osteoporosis, immunology, neurobiology, cellular & molecular biology, and diabetes research.

Note: Other applications include agriculture, forensics, and environmental applications.

Genomics Market Assessment—by End User

Pharmaceutical & Biotechnology CompaniesHospitals & ClinicsDiagnostics LaboratoriesContract Research Organizations (CROs)Academic & Research InstitutesOther End Users

Note: Other end users include food & beverage companies, agricultural companies, and forensics.

Browse In-depth Report Now – https://www.meticulousresearch.com/product/genomics-market-1262

Genomics Market Assessment—by Geography

North AmericaU.S.CanadaEuropeGermanyFranceU.K.ItalySpainRest of EuropeAsia-PacificChinaJapanIndiaRest of Asia-PacificLatin AmericaBrazilMexicoRest of Latin AmericaMiddle East & Africa

Browse More Related Reports –

Animal Genetics Market is projected to hit $9.12 billion by 2031, growing at a CAGR of 5.8% from 2024. Discover key trends driving this growth – https://www.meticulousresearch.com/product/animal-genetics-market-5863

Spatial Genomics & Transcriptomics Market is projected to reach $3.23 billion by 2031 at a CAGR of 27.8% from 2024 to 2031  – https://www.meticulousresearch.com/product/spatial-genomics-market-5763

According to this latest publication from Meticulous Research,genetic testing market is projected to reach $ 28.24 billion by 2030, at a CAGR of 10.4% – https://www.meticulousresearch.com/product/genetic-testing-market-5370

Global Artificial Intelligence in genomics market is slated to register a CAGR of 42.8% during forecast period 2022–2029 to reach $6.22 billion by 2029 – https://www.meticulousresearch.com/product/ai-in-genomics-market-5345

Next Generation Sequencing For Industry Outlook is projected to reach $42.7 billion by 2031 at a CAGR of 15.7% from 2024 to 2031 – https://www.meticulousresearch.com/product/NGS-market-industry-outlook-5957

NGS Automation Market is expected to grow at a CAGR of 13.4% from 2022–2029 to reach $1.33 billion by 2029 – https://www.meticulousresearch.com/product/ngs-automation-market-5271

Saudi Arabia’s NGS market, valued at $24.4 Million in 2023, is projected to grow to $50 Million by 2031, with a CAGR of 10.1% from 2024 to 2031 – https://www.meticulousresearch.com/product/saudi-arabia-ngs-market-6002

Latin America NGS Market is expected to register a CAGR of 13.9% from 2024 to 2031 to reach $765.2 million by 2031 – https://www.meticulousresearch.com/product/latin-america-ngs-market-5780

Asia-Pacific Next Generation Sequencing (NGS) Market is expected to grow at a CAGR of 16.9% from 2024 to 2030 to reach $6.38 billion by 2030 – https://www.meticulousresearch.com/product/asia-pacific-next-generation-sequencing-market-5722

North America NGS Market to be worth $13.7 billion by 2030, growing at a 16% CAGR from 2024–2030 – https://www.meticulousresearch.com/product/north-america-ngs-market-5607

Genomics Market Report Summary:

Particulars

Details

Number of Pages

320

Format

PDF

Forecast Period

2024-2031

Base Year

2023

CAGR (2024–2031)

11.1 %

Estimated Market Size (Value)

$70.52 Billion by 2031

Segments Covered

 By Offering

InstrumentsConsumablesSoftwareServices

 By Technology

Polymerase Chain Reaction (PCR)SequencingNGSOther Sequencing TechnologiesNucleic Acid Extraction and PurificationMicroarrayOther Technologies
(Note 1: Other sequencing technologies include pyrosequencing, degradome sequencing, Sanger sequencing, Chromatin Immunoprecipitation (ChIP) sequencing, and methylation sequencing.
Note 2: Other technologies include cell counting, transfection, and gene editing.)

 By Application

DiagnosticsDrug Discovery & DevelopmentLife Science ResearchCancer ResearchStem Cell ResearchOther Life Science ResearchOther Applications
(Note 1: Other life science research applications include cardiovascular diseases, osteoporosis, immunology, neurobiology, cellular and molecular biology, and diabetes research.
Note 2: Other applications include agriculture, forensics, and environmental applications.)

 By End User

Pharmaceutical & Biotechnology CompaniesHospitals & ClinicsDiagnostics LaboratoriesContract Research Organizations (CROs)Academic & Research InstitutesOther End Users
(Note: Other end users include food & beverage companies, agricultural companies, and forensics.)

Countries Covered

North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Latin America (Brazil, Mexico, Rest of Latin America), and the Middle East & Africa

Key Companies Profiled

Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Danaher Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Illumina, Inc. (U.S.), QIAGEN N.V. (Netherlands), Pacific Biosciences of California, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K.), Eppendorf SE (Germany), Myriad Genetics, Inc. (U.S.), Revvity, Inc. (Formerly PerkinElmer, Inc.) (U.S.), and BGI Genomics Co. Ltd (China)

Click here to: Get Free Sample Pages of this Report

Hot Industry Reports: Emerging Trends and Market Forecasts –

Automated Material Handling Systems Market Size, Share, & Report 2030 – https://www.meticulousresearch.com/product/automated-material-handling-systems-market-5149

Healthcare Cybersecurity Market Size, Share, & Report 2031 – https://www.meticulousresearch.com/product/healthcare-cybersecurity-market-5116

Direct to Consumer (DTC) Pet Food Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/direct-to-consumer-pet-food-market-5146

Haematococcus Pluvialis Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/haematococcus-pluvialis-market-5142

South East Asia English Language Learning Market by Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/south-east-asia-english-language-learning-market-5677

Interactive Display Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/interactive-display-market-5125

Semiconductor and Circuit Manufacturing Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/semiconductor-and-circuit-manufacturing-market-5092

Automotive Powertrain Sensors Market Trends & Forecast – https://www.meticulousresearch.com/product/automotive-powertrain-sensors-market-5155

Water Quality Testing Market Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/water-quality-testing-market-5501

Clear Aligners Market Size, Share & Trends: 2023 to 2030 – https://www.meticulousresearch.com/product/clear-aligners-market-5331

Testing, Inspection and Certification Market 2030 Key Trends – https://www.meticulousresearch.com/product/testing-inspection-and-certification-market-5151

Power Tools Market: Size, Share, Trends, & Forecast Analysis – https://www.meticulousresearch.com/product/power-tools-market-5810

Medical Laser Market Growth & Share Insights 2024 – 2031 – https://www.meticulousresearch.com/product/medical-lasers-market-5196

Laser Technology Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/laser-technology-market-5189

Dialysis Market Size, Share, Growth, & Trends Report 2031 – https://www.meticulousresearch.com/product/dialysis-market-5137

Tertiary Water and Wastewater Treatment Technologies Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/tertiary-water-and-wastewater-treatment-technologies-market-5185

Parking Management Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/parking-management-market-5094

Dunaliella Salina Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/dunaliella-salina-market-5168

Electric Car Market: Power Trends & Forecasts 2024 – https://www.meticulousresearch.com/product/electric-car-market-5187

Pharmaceutical Contract Development and Manufacturing Market – https://www.meticulousresearch.com/product/pharmaceutical-contract-development-and-manufacturing-market-5171

Delivery Drones Market: Trends, Size & Forecasts to 2031 – https://www.meticulousresearch.com/product/delivery-drones-market-5193

Electric Vehicle Market Trends & Forecast Analysis – https://www.meticulousresearch.com/product/electric-vehicle-market-5179

IoT Sensors Market Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/iot-sensors-market-5738

Virtualized Evolved Packet Core Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/virtualized-evolved-packet-core-market-5201

Seaweed Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/seaweed-market-5183

Dental 3D Printing Material Market Size, Share, Growth, & Trends – https://www.meticulousresearch.com/product/dental-3d-printing-material-market-5204

SCADA Market Size, Share, Forecast, & Trends Analysis – https://www.meticulousresearch.com/product/scada-market-5186

IoT Security Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/iot-security-market-5254

Electric Scooter Market Size, Share, Report, & Trends 2031 – https://www.meticulousresearch.com/product/electric-scooter-market-5191

Canada Black Soldier Fly Market by Size, Share, Forecasts, & Trends Analysis – https://www.meticulousresearch.com/product/canada-black-soldier-fly-market-5230

Contact:
Mr. Khushal Bombe
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe: +44-203-868-8738
APAC: +91 744-7780008
Email- mailto:sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Meticulousblog.org | Top Market Research Reports Blog – https://meticulousblog.org/
Content Source: https://www.meticulousresearch.com/pressrelease/245/genomics-market

Photo: https://mma.prnewswire.com/media/2514303/Genomics_Market_Size.jpg
Logo: https://mma.prnewswire.com/media/1757980/Meticulous_Research_Logo_1.jpg

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/genomics-market-to-reach-70-52-billion-by-2031–driven-by-increasing-incorporation-of-genomic-data-in-clinical-workflows-and-increasing-funding-and-investments-in-genomics-projects—exclusive-report-by-meticulous-research-302257383.html

SOURCE Meticulous Market Research Pvt. Ltd.

Continue Reading

Technology

Warhound Launches with $200 Million to Rebuild America’s Military Working Dog Supply, Using Advanced Genetics and Defense Technology

Published

on

By

Company will produce genetically enhanced working dogs that leverage cybernetics technology to improve health and performance while ending reliance on foreign suppliers

DALLAS and COSTA MESA, Calif., Oct. 23, 2026 /PRNewswire/ — Warhound, a new defense technology company conceived by American technology entrepreneurs Ben Lamm and Palmer Luckey emerged from stealth with a $200 million seed round. Warhound will rebuild America’s domestic supply of elite working dogs for U.S. military forces, law-enforcement, emergency first response teams—a critical national security resource that the U.S. has long relied on foreign countries to provide. Led by CEO David Spirk, the company will reduce dependence on a shrinking European supply chain and strengthen America’s ability to protect its own people, infrastructure, and national security interests.

Warhound is modernizing America’s working-dog program by delivering a vertically integrated program, combining Colossal’s enhanced genetics platform and secure biobanking capabilities of America’s top-performing dog arsenal, controlled delivery through cloning with best-in-class training and animal care. Through a partnership, all dogs will be equipped by Anduril’s advanced cybernetic Augments, software, and battlefield situational awareness. The company is backed by In-Q-Tel, Sequoia Capital, ARK Invest, Franklin Templeton, 8VC, USIT, Bob Nelsen, Breyer Capital, CAZ Investments, Neogenesis, Builders VC, and Lux Capital among others. Based in Texas, Warhound will operate under the guidance of the American Humane Society which will certify its training programs and support the reunification of retired military working dogs with their former handlers and adoption protocols.

“Palmer, Ben and the Warhound team are exceptional. Sequoia is proud to back them,” said Shaun Maguire, Partner at Sequoia Capital.

Warhound is bringing together Colossal’s breakthroughs in genetics, cloning, and animal biology with Anduril’s advanced defense technology to fundamentally change how America produces, trains, and protects its military working dogs. Colossal’s science will help produce healthier dogs with characteristics suited to demanding missions, while Anduril’s technology will give dogs and their handlers greater awareness and protection in the field.

“Every day, we ask dogs to put their lives on the line to protect ours. They detect explosives, protect our troops, and run toward dangers that most people are trained to run away from. Yet we’re still relying on outdated approaches to breeding and training these extraordinary animals, with too many never making it through the process. We have an opportunity to fundamentally change that. Colossal has spent years pioneering breakthroughs in genetics, cloning, and animal biology, and now we’re applying that science to give these dogs the best possible chance at a long, healthy life and a successful mission. If we’re going to ask man’s best friend to protect America, we owe it to them to use every tool at our disposal to protect them, too,” said Ben Lamm.

Since the Army established the K-9 Corps in 1942, military working dogs have served alongside America’s armed forces for more than 84 years—detecting threats, protecting service members and supporting missions worldwide. That program has evolved in The United States Department of War’s (DOW) Military Working Dog Program, which currently includes 2,200+ working dog teams that are operationally critical for detection and patrol work, and a critical part of the defense infrastructure of the country. More than 80% of U.S. military working dogs are currently acquired from Europe, creating a critical interdependency on foreign nations for an asset the Pentagon itself calls irreplaceable. That dependency is compounding: after a rigorous, roughly three-year acquisition-and-training pipeline, less than half of the dogs procured are ultimately deemed fit for service, meaning the U.S. must source and train roughly 200 dogs today to field 100 working animals tomorrow.

“Man’s best friend deserves man’s best tech,” said Palmer Luckey. 

David Spirk has been named the CEO of Warhound. As a veteran of the United States Marine Corps, he worked as an intelligence specialist with multiple deployments and ultimately served as the Deputy Associate Director of National Intelligence for Afghanistan and Pakistan at the Office of the Director of National Intelligence representing the Intelligence Community at the White House and on Capital Hill. He has an extensive background in the U.S. military, intelligence community, and federal data governance, specifically focused on scaling algorithmic warfare and creating data driven advantages. More recently, he was a Senior Counselor at Palantir Technologies where he focused on expanding the company’s software footprints across the U.S. government, allied international partners, and commercial sectors. Previously, he was appointed the First Chief Data Officer (CDO) for the Department of War, where he worked on accelerating the military’s data-driven capabilities and was the first CDO for the U.S. Special Operations Command (USSOCOM).

“Our long-term goal is simple: healthier dogs, better-prepared teams, and more service members and first responders coming home safely. Leading Warhound, and strengthening America’s working-dog capabilities, is an opportunity to apply my experience to a mission I care deeply about: protecting people and helping the animals who support them,” said David Spirk. “My focus is building a team that can turn scientific advances into capabilities that work in the field.”

Building Healthier, More Capable Working Dogs to Protect Both Dogs and People
The concept of Warhound was conceived years ago by Palmer and Ben after a discussion at Peter Diamandis’ Moonshots Summit. Military working-dog programs face a costly challenge: more than half of candidate dogs fail to complete training, while reliance on overseas breeders leaves the United States dependent on a constrained foreign supply chain. Warhound was created to improve that system—producing fewer dogs with a greater likelihood of remaining healthy, completing training, and succeeding in their missions.

Warhound dog-and-handler teams will also connect Anduril’s integrated capabilities—including eye and ear protection and Eagle Eye technology—will help safeguard working dogs, their handlers and the wider unit while supporting safer, more effective missions.

“For millennia, people have selectively bred dogs to be companions and helpmates. Modern biotechnology gives us a more precise way to shape some of their traits, thus improving both the work dogs do and their own health and well-being,” said Alta Charo, Warren P. Knowles Professor Emerita of Law and Bioethics at the University of Wisconsin–Madison. “The Warhound project offers the possibility of improving working dogs’ health and welfare while supporting the lifesaving work they do. But we still must look carefully at who benefits, what risks the animals bear, and how concern for animal welfare translates into practice through careful evaluation of the evidence, meaningful oversight, and responsibility for the dogs throughout their lives, including retirement. The American Humane Society brings valuable experience through its military working dog reunification efforts and Pups4Patriots program. That experience provides a foundation, but public trust has to be earned through the care we provide and the commitments we keep.”

Animal welfare is central to the program. By improving health, durability, and training success, Warhound will significantly reduce washouts, limit the number of dogs unnecessarily entering intensive training and enable safer, more effective missions. Technologies and therapeutics developed through the program will also be made available to all dogs and ultimately improve the health of all dogs, not only those serving alongside America’s service men and women. Together, these capabilities will establish a secure domestic supply of military working dogs while giving American service members healthier, more capable canine partners.

“Working dogs are extraordinary animals whose courage and loyalty save lives,” said Dr. Robin Ganzert, President and CEO of American Humane Society. “We owe these dogs a commitment to their well-being that matches their service to us. What excites me about Warhound is the opportunity to make health, welfare, and exceptional care fundamental to a working-dog program from the very beginning. Success means helping these dogs thrive throughout their lives—from training and active service to the loving, dignified retirement every canine hero deserves.”

Warhound is built to take today’s level of performance and make it better: using cutting edge engineering and technology, on American soil, from American companies, without the wait times, price volatility, or geopolitical exposure of a foreign supply chain.

About Warhound
Warhound is a Texas-based defense technology company building a secure domestic supply of healthier, more capable working dogs for the U.S. military, law enforcement and emergency responders. Conceived by Palmer Luckey and Ben Lamm, Warhound combines biotechnology licensed from Colossal Biosciences with advanced training and Anduril’s cybernetic augments and software. The company aims to reduce reliance on foreign suppliers, improve canine health and performance, and enhance safety for dogs and their handlers. Animal welfare is central to Warhound’s mission, with a commitment to lifelong care from birth through training, service and retirement. To follow along, please visit: warhound.com.

About Anduril
Anduril Industries is a defense technology company that builds autonomous systems and a common operating layer to give the United States and its allies a persistent advantage in sensing, decision-making, and force projection.

About the American Humane Society
The American Humane Society is the country’s first national humane organization and a global leader in animal welfare. Founded in 1877, American Humane has been at the forefront of protecting animals, rescuing them from cruelty, abuse, and natural disasters, and setting the gold standard in science-based welfare certifications. The organization oversees prominent programs including the iconic “No Animals Were Harmed®” film and television certification, the American Humane Certified™ farm and zoo standards, military working dog reunifications, and the Pups4Patriots™ service dog program. Learn more at americanhumane.org. 

About Colossal Biosciences
Colossal was founded by emerging technology and software entrepreneur Ben Lamm and world-renowned geneticist and serial biotech entrepreneur George Church, Ph.D., and is the first to apply CRISPR technology for the purposes of species de-extinction. Colossal creates innovative technologies for species restoration, critically endangered species protection and the repopulation of critical ecosystems that support the continuation of life on Earth. Colossal is accepting humanity’s duty to restore Earth to a healthier state, while also solving for the future economies and biological necessities of the human condition through cutting-edge science and technologies. To follow along, please visit: www.colossal.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/warhound-launches-with-200-million-to-rebuild-americas-military-working-dog-supply-using-advanced-genetics-and-defense-technology-302918435.html

SOURCE Warhound

Continue Reading

Technology

Best Version Media Names Chris Laurence Next CEO; Kevin O’Brien Transitions to CRO

Published

on

By

Leadership investment strengthens companywide execution and sharpens focus on Publisher success and revenue growth

BROOKFIELD, Wis., Oct. 23, 2026 /PRNewswire/ — Best Version Media (BVM), a local media and marketing company serving more than 1,300 communities across the United States and Canada, today announced that Chris Laurence has joined the company as Chief Executive Officer. Kevin O’Brien, who previously served as CEO, will transition to Chief Revenue Officer, focusing on leading BVM’s sales field and accelerating revenue growth.

The appointments reflect BVM’s investment in leadership to support its next stage of growth. By establishing dedicated executive leadership for the broader organization and the sales field, BVM is strengthening its ability to execute across the business while supporting its independent Publishers and the local businesses they serve.

“Our growth has brought us to a point where leading the overall company and leading our sales field each deserve a dedicated focus,” said O’Brien. “This transition allows me to concentrate on working with our sales leaders and Publishers, strengthening the field, and helping more local businesses connect with their communities. I’m excited to partner with Chris as we build on BVM’s momentum.”

Laurence brings experience as CEO, CFO, and COO of public, private, and private equity-backed companies, where he has led growth, operational improvement, and technology transformation. Before moving into operating roles, he was a general partner at Brentwood Associates, a Los Angeles-based private equity firm.

“BVM has built a powerful combination of community storytelling, local relationships, and marketing solutions for small businesses,” said Laurence. “I look forward to working with Kevin and the entire team to build on that foundation, strengthen how we operate, and support the success of our Publishers and clients.”

As CEO, Laurence will lead BVM’s overall strategy and operations, working with the team to scale operations and support the success of our Publishers and the local businesses they serve. As CRO, O’Brien will focus on sales leadership, Publisher growth, and revenue generation. Together, they will help advance BVM’s print and digital offerings and position the company for continued growth.

About Best Version Media

Founded in 2007, Best Version Media (BVM) connects local businesses with customers through community magazines, targeted digital advertising, and online presence management tools. Serving more than 1,300 communities across the United States and Canada, BVM’s network of independent Publishers builds relationships with local businesses and brings community stories to life. BVM is a portfolio company of H.I.G. Capital. To learn more, visit www.bestversionmedia.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/best-version-media-names-chris-laurence-next-ceo-kevin-obrien-transitions-to-cro-302918458.html

SOURCE Best Version Media, LLC

Continue Reading

Technology

Dow and Small Caps Climb Weekly While Nasdaq Slips on Megacap Earnings Charges

Published

on

By

VANCOUVER, BC, Oct. 23, 2026 /PRNewswire/ — Stock Preachers News Commentary – Stocks closed a volatile earnings week with a split verdict: the Dow gained 0.64% and the Russell 2000 jumped 2.07%, while the Nasdaq Composite fell 0.45% and the S&P 500 slipped 0.22%. The VIX rose to 19.40 and the VXN climbed to 28.13 as traders weighed a wave of third-quarter results. Gold dropped 3.47% and silver fell 4.90% on the week, while WTI crude rose 3.74% on Thursday alone. The 10-year Treasury yield eased 11 basis points to 4.99%. Active Companies from around the markets with current developments this week include: Meta Platforms, Inc. (Nasdaq: META), Texas Instruments Incorporated (Nasdaq: TXN), RTX (NYSE: RTX), IBM (NYSE: IBM), and First Citizens BancShares, Inc. (Nasdaq: FCNCA).

Large-cap benchmarks diverged sharply this week. The Dow closed at 52,337.54, up 0.64% for the week despite a 1% drop on Friday, while the S&P 500 ended at 7,642.22, down 0.22% weekly after touching a week high of 7,770.40. The Nasdaq Composite settled at 26,022.45, down 0.45% on the week, dragged by a rough stretch for megacap tech following a batch of earnings reports.

The Russell 2000 was the standout, closing at 2,777.63 for a 2.07% weekly gain, outperforming its large-cap peers as investors rotated toward smaller names. RSI readings show the Nasdaq at 38.9 and the S&P 500 at 43.5, both in cooler territory, while the Dow’s RSI of 54.1 reflects its relative strength this week.

Volatility ticked higher into the weekend, with the VIX up 0.96 points for the week to 19.40 and the VXN up a full point to 28.13. In commodities, natural gas spiked 8.66% on Thursday alone even as it remained down 0.65% for the week, while copper rose 2.44% daily. The dollar firmed slightly against the euro, with EUR/USD down 0.24% on the week to 1.12.

The full report also breaks down key support and resistance levels for each index, additional earnings movers, and sentiment heading into next week’s sessions.

CONTINUED… Read this and more news for Meta Platforms, Inc. (Nasdaq: META), Texas Instruments Incorporated (Nasdaq: TXN), RTX (NYSE: RTX), IBM (NYSE: IBM), and First Citizens BancShares, Inc. (Nasdaq: FCNCA) at: https://stockpreachers.com/articles/small-caps-lead-big-tech-lags-as-earnings-season-shakes-the-tape/

In other industry developments and happenings in the market this week include:

Meta Platforms, Inc. (Nasdaq: META) Meta reported third-quarter revenue of $64.60 billion, up 26% year over year, but net income of $9.86 billion reflected a $9.89 billion charge tied to an agreement with 52 state attorneys general over teen mental health and social media litigation. Diluted EPS was $3.83, up 265% year over year; excluding the litigation charge, EPS would have been $7.40.

Operating margin fell to 20% from 40% a year earlier, while costs and expenses rose 68% to $51.61 billion. Capital expenditures, including finance lease payments, totaled $34.91 billion, and free cash flow was negative $2.12 billion for the quarter.

“We hit major milestones this quarter toward delivering personal superintelligence for everyone – including launching Muse and Muse Wonder, our first frontier model,” said Mark Zuckerberg, Meta founder and CEO. “Our investments are paying off, the core business is strong, and we’re seeing velocity across the board.” The company guided fourth-quarter revenue to a range of $73-76 billion and raised full-year 2026 total expense guidance to $175-179 billion. Read the release.

Texas Instruments Incorporated (Nasdaq: TXN) Texas Instruments reported third-quarter revenue of $6.06 billion, up 28% from a year earlier, with net income of $2.43 billion and earnings per share of $2.62. Operating profit rose 73% to $2.87 billion, and revenue increased 11% sequentially.

“Revenue increased 11% sequentially and 28% from the same quarter a year ago with continued broad growth in industrial, automotive and data center,” said Haviv Ilan, TI’s chairman, president and CEO. Trailing 12-month cash flow from operations was $9.9 billion, with free cash flow of $8.4 billion.

The company returned $5.8 billion to shareholders over the trailing 12 months and guided fourth-quarter revenue to a range of $5.80 billion to $6.30 billion, with earnings per share expected between $2.45 and $2.79. Read the release.

RTX (NYSE: RTX) RTX reported third-quarter sales of $25.0 billion, up 11% versus the prior year and 12% organically, with adjusted EPS of $2.26, up 33% from a year earlier. GAAP EPS was $1.89. Operating cash flow was $2.9 billion and free cash flow was $2.1 billion, with results including $0.25 of IEEPA cost recovery per share.

The company’s backlog reached a record $340 billion, including $176 billion commercial and $164 billion defense, after over $81 billion of new awards including Tomahawk and AMRAAM multi-year production contracts.

“Our strong execution and operational focus in the third quarter enabled RTX to deliver double-digit organic sales growth across commercial aerospace and defense,” said RTX Chairman and CEO Chris Calio. The company raised its full-year adjusted EPS outlook to $7.65-$7.75 and adjusted sales guidance to $97.0-$97.5 billion. Read the release.

IBM (NYSE: IBM) IBM reported third-quarter revenue of $17.1 billion, up 5% as reported and 6% at constant currency, with Software revenue up 8% and Infrastructure revenue up 4%. GAAP diluted earnings per share were $2.31, up 26% year over year, while operating (non-GAAP) EPS was $2.95, up 11%.

The company generated $4.0 billion in net cash from operating activities in the quarter and $3.0 billion in free cash flow, up $0.7 billion year over year. Year to date, free cash flow reached $7.8 billion.

“Disciplined execution throughout the quarter drove accelerated revenue growth and strong free cash flow,” said Arvind Krishna, IBM chairman, president and chief executive officer. IBM now expects full-year free cash flow to increase by more than $1 billion year over year, while continuing to guide constant currency revenue growth of four to five percent. Read the release.

First Citizens BancShares, Inc. (Nasdaq: FCNCA) First Citizens BancShares reported third-quarter net income of $606 million, down from $672 million in the linked quarter. Net income available to common stockholders was $577 million, or $51.23 per common share, a $63 million decrease from the prior quarter’s $640 million.

Net interest income rose to $1.70 billion, up $43 million from the linked quarter, while net interest margin declined 3 basis points to 3.07%. The company completed its BMO Branch Acquisition on September 4, 2026, assuming approximately $4.9 billion in deposits and acquiring approximately $650 million in loans.

“We returned $600 million to our stockholders through share repurchases and further optimized our balance sheet by repaying another $8.0 billion of the Purchase Money Note,” said Chairman and CEO Frank B. Holding, Jr. The board approved a new repurchase plan authorizing up to $1.2 billion of Class A common shares through 2027. Read the release.

Contact Information:

https://stockpreachers.com

Media Contact: info@stockpreachers.com

DISCLAIMER: Nothing in this article should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a market commentary and is not a paid advertisement. This article is being distributed by Stock Preachers, which is wholly owned and operated by Market Equities Limited (“MEL”), a company incorporated under the laws of Ireland. This is an independent market commentary published on a non-paid basis. MEL has not been paid any fee by any company mentioned in this article for its production or distribution, and MEL has no advertising or digital media agreement with any company mentioned in this article. The companies mentioned have not reviewed or approved this article. Market Equities and its owners, operators, directors, and affiliates may, from time to time, hold positions in securities mentioned in this article or in the broad-market index funds that track them, and reserve the right to buy, sell, or hold such securities at any time without further notice. Information in this article was obtained from sources believed to be reliable, including company news releases and public market data, but its accuracy cannot be guaranteed. Market data is as of the time stated and may be delayed. Portions of this commentary were produced with the assistance of automated tools from that data and reviewed against it. Investing in securities involves risk, including the possible loss of some or all of your investment. Technical analysis describes past price and volume behavior and does not predict future results; support and resistance levels can fail at any time. References to the companies named in this article are provided solely as market and sector context and as summaries of each company’s own public news releases. No partnership, affiliation, or endorsement is implied, and nothing in this article is a recommendation to buy, sell, or hold any security. Quotations attributed to company executives are reproduced from those companies’ own news releases. Forward-Looking Statements: This article may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements made by the companies mentioned in their own news releases. Such statements involve risks and uncertainties, and actual results may differ materially. Readers should review each company’s filings with the SEC and applicable Canadian securities regulators. Eagle Eye is an investor signal-intelligence platform affiliated with the publisher of this article. Eagle Eye is not a broker-dealer, and nothing it provides is investment advice. Data may be delayed. Always do your own research.

View original content to download multimedia:https://www.prnewswire.com/news-releases/dow-and-small-caps-climb-weekly-while-nasdaq-slips-on-megacap-earnings-charges-302918459.html

SOURCE Stock Preachers

Continue Reading

Trending